AU2016286091B2 - Therapeutic compositions, combinations, and methods of use - Google Patents

Therapeutic compositions, combinations, and methods of use Download PDF

Info

Publication number
AU2016286091B2
AU2016286091B2 AU2016286091A AU2016286091A AU2016286091B2 AU 2016286091 B2 AU2016286091 B2 AU 2016286091B2 AU 2016286091 A AU2016286091 A AU 2016286091A AU 2016286091 A AU2016286091 A AU 2016286091A AU 2016286091 B2 AU2016286091 B2 AU 2016286091B2
Authority
AU
Australia
Prior art keywords
cancer
administered
tumor
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016286091A
Other languages
English (en)
Other versions
AU2016286091A1 (en
Inventor
Jonathan A. Pachter
Jennifer E. Ring
Yan Wang
David T. Weaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of AU2016286091A1 publication Critical patent/AU2016286091A1/en
Application granted granted Critical
Publication of AU2016286091B2 publication Critical patent/AU2016286091B2/en
Priority to AU2021202379A priority Critical patent/AU2021202379B2/en
Priority to AU2023214272A priority patent/AU2023214272B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016286091A 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use Active AU2016286091B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021202379A AU2021202379B2 (en) 2015-06-29 2021-04-19 Therapeutic compositions, combinations, and methods of use
AU2023214272A AU2023214272B2 (en) 2015-06-29 2023-08-09 Therapeutic compositions, combinations, and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186197P 2015-06-29 2015-06-29
US62/186,197 2015-06-29
PCT/US2016/040080 WO2017004192A1 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202379A Division AU2021202379B2 (en) 2015-06-29 2021-04-19 Therapeutic compositions, combinations, and methods of use

Publications (2)

Publication Number Publication Date
AU2016286091A1 AU2016286091A1 (en) 2018-02-22
AU2016286091B2 true AU2016286091B2 (en) 2021-02-04

Family

ID=57609144

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016286091A Active AU2016286091B2 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use
AU2021202379A Active AU2021202379B2 (en) 2015-06-29 2021-04-19 Therapeutic compositions, combinations, and methods of use
AU2023214272A Expired - Fee Related AU2023214272B2 (en) 2015-06-29 2023-08-09 Therapeutic compositions, combinations, and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021202379A Active AU2021202379B2 (en) 2015-06-29 2021-04-19 Therapeutic compositions, combinations, and methods of use
AU2023214272A Expired - Fee Related AU2023214272B2 (en) 2015-06-29 2023-08-09 Therapeutic compositions, combinations, and methods of use

Country Status (13)

Country Link
US (3) US10532056B2 (enExample)
EP (2) EP4488265A3 (enExample)
JP (3) JP2018519327A (enExample)
KR (1) KR102783581B1 (enExample)
CN (2) CN114209841A (enExample)
AU (3) AU2016286091B2 (enExample)
CA (2) CA2991044C (enExample)
EA (1) EA201890161A1 (enExample)
ES (1) ES2987376T3 (enExample)
IL (2) IL322086A (enExample)
MX (2) MX389683B (enExample)
WO (1) WO2017004192A1 (enExample)
ZA (1) ZA201800572B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819398T3 (es) 2013-07-18 2021-04-15 Taiho Pharmaceutical Co Ltd Agente terapéutico para el cáncer resistente al inhibidor de FGFR
TWI574691B (zh) 2013-07-18 2017-03-21 Taiho Pharmaceutical Co Ltd Anti - tumor agents for intermittent administration of FGFR inhibitors
US20150190346A1 (en) * 2014-01-09 2015-07-09 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
EP4039260B1 (en) 2017-02-07 2024-04-17 Saitama Medical University Cd62llow cd4+ t-cells for treating or preventing cancer
WO2018187740A1 (en) 2017-04-07 2018-10-11 Shasqi, Inc. Bioorthogonal compositions
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
WO2019018666A1 (en) * 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
JP2021517589A (ja) * 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
RU2759746C1 (ru) 2018-03-19 2021-11-17 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция, включающая алкилсульфат натрия
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
CA3125058C (en) * 2018-12-27 2023-10-03 Hinova Pharmaceuticals Inc. Fak inhibitor and drug combination thereof
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
TW202035702A (zh) 2019-02-20 2020-10-01 學校法人埼玉醫科大學 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記
WO2020175704A1 (ja) * 2019-02-28 2020-09-03 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
TWI757716B (zh) * 2019-04-15 2022-03-11 禾榮科技股份有限公司 微創型中子束產生裝置及微創型中子捕獲治療系統
JP7199523B2 (ja) 2019-05-10 2023-01-05 富士フイルム株式会社 光照射装置およびセンサー
CN110201171A (zh) * 2019-06-18 2019-09-06 北京大学 Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用
CA3143989A1 (en) * 2019-06-21 2020-12-24 Board Of Regents - The University Of Texas System Targeting alpha3beta1 integrin for treatment of cancer and other diseases
CN114340680A (zh) * 2019-07-05 2022-04-12 坦博公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
BR112022010319A2 (pt) 2019-11-28 2022-08-16 Inxmed Nanjing Co Ltd Uso de bi853520 no tratamento de câncer
BR112022015161A2 (pt) * 2020-01-31 2022-10-11 Verastem Inc Terapia de combinação para tratamento de crescimento celular anormal
CN115052603B (zh) * 2020-02-05 2023-12-19 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用
JP7470775B2 (ja) 2020-02-14 2024-04-18 富士フイルム株式会社 光結合システムおよび光通信デバイス
KR20230039684A (ko) * 2020-07-13 2023-03-21 베라스템, 인코포레이티드 비정상적 세포 성장을 치료하기 위한 조합 요법
PE20231303A1 (es) * 2020-08-03 2023-08-24 Inxmed Nanjing Co Ltd Forma solida de compuesto
WO2022125652A1 (en) * 2020-12-08 2022-06-16 Cornell University Methods of inducing an immunomodulatory tumor response
CN117015377A (zh) * 2020-12-11 2023-11-07 材料治疗公司 使用波生坦与检查点抑制剂组合的癌症治疗
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
WO2023104151A1 (zh) * 2021-12-10 2023-06-15 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
EP4545080A1 (en) * 2022-06-24 2025-04-30 Inxmed (Nanjing) Co., Ltd. Pharmaceutical combination for treating tumors and use thereof
JP2025528528A (ja) * 2022-09-05 2025-08-28 ▲應▼世生物科技（南京）有限公司 Ｆａｋ阻害剤及びｅｇｆｒ－ｔｋｉの薬学的組合せ及び使用
EP4588485A1 (en) * 2022-09-16 2025-07-23 Inxmed (Nanjing) Co., Ltd. Pharmaceutical combination of fak inhibitor and topoisomerase inhibitor and use thereof
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
AU2024211503A1 (en) * 2023-01-24 2025-07-31 Msd International Business Gmbh Methods and compositions for combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
FI20030976A7 (fi) 2003-06-30 2004-12-31 M Real Oyj Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi
EP1761132B1 (en) 2004-06-30 2011-11-23 Cadbury Holdings Limited Chewing gum comprising flavor emulsion
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
ES2485040T3 (es) 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
WO2008129380A1 (en) * 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
MX2010014057A (es) 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
US9192604B2 (en) * 2011-06-28 2015-11-24 Glaxosmithkline Intellectual Property (No. 2) Limited Method of administration and treatment
HK1214128A1 (zh) * 2012-10-05 2016-07-22 Bluelink Pharmaceuticals, Inc. 癌症的治療
WO2015061796A1 (en) 2013-10-25 2015-04-30 Nodality Inc. Methods and compositions for immunomodulation
WO2015063647A1 (en) * 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
WO2015120289A1 (en) 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
WO2017201043A1 (en) 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAZARO et al.: "Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response" Endocrine-Related Cancer, 2013, vol. 20, no. 5, pp. 691-704 *

Also Published As

Publication number Publication date
IL256652B1 (en) 2025-11-01
EP3313404A1 (en) 2018-05-02
JP2024111247A (ja) 2024-08-16
NZ739490A (en) 2024-11-29
EP3313404B1 (en) 2024-09-04
CA3244408A1 (en) 2025-06-13
HK1254525A1 (en) 2019-07-19
ZA201800572B (en) 2023-12-20
EA201890161A1 (ru) 2018-06-29
IL322086A (en) 2025-09-01
MX2022001165A (es) 2022-02-22
AU2021202379B2 (en) 2023-05-11
EP4488265A2 (en) 2025-01-08
AU2016286091A1 (en) 2018-02-22
US20200330471A1 (en) 2020-10-22
JP2018519327A (ja) 2018-07-19
BR112017028519A2 (en) 2018-08-28
MX389683B (es) 2025-03-20
CN108289892A (zh) 2018-07-17
US10532056B2 (en) 2020-01-14
EP4488265A3 (en) 2025-04-02
EP3313404A4 (en) 2019-08-07
AU2023214272A1 (en) 2023-08-31
WO2017004192A1 (en) 2017-01-05
CA2991044C (en) 2024-11-19
CA2991044A1 (en) 2017-01-05
KR102783581B1 (ko) 2025-03-17
US20240000790A1 (en) 2024-01-04
ES2987376T3 (es) 2024-11-14
US20180177788A1 (en) 2018-06-28
EP3313404C0 (en) 2024-09-04
AU2023214272B2 (en) 2025-08-14
CN108289892B (zh) 2021-11-23
CN114209841A (zh) 2022-03-22
JP2021183650A (ja) 2021-12-02
IL256652A (en) 2018-02-28
KR20180100539A (ko) 2018-09-11
NZ777396A (en) 2025-03-28
MX2018000288A (es) 2018-11-09
AU2021202379A1 (en) 2021-05-13
US11564927B2 (en) 2023-01-31

Similar Documents

Publication Publication Date Title
AU2021202379B2 (en) Therapeutic compositions, combinations, and methods of use
US12280050B2 (en) Therapeutic compositions, combinations, and methods of use
KR20240041978A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
HK40121585A (en) Therapeutic compositions, combinations, and methods of use
HK1254525B (en) Therapeutic compositions, combinations, and methods of use
EA042150B1 (ru) Терапевтические композиции, комбинации и способы применения
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
WO2016109426A1 (en) Oral dosing regimen of a dual mtor and pi3 inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)